Dynamics of Hepatitis B Virus Resistance to Lamivudine

Lamivudine was the first approved inhibitor of hepatitis B virus (HBV) reverse transcriptase (RT). Lamivudine resistance develops in 53% to 76% of patients after 3 years of treatment. We extensively characterized the dynamics of HBV quasispecies variant populations in four HBV-infected patients who...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Pallier, Coralie, Castéra, Laurent, Soulier, Alexandre, Hézode, Christophe, Nordmann, Patrice, Dhumeaux, Daniel, Pawlotsky, Jean-Michel
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2006
Teme:
Vaccines and Antiviral Agents
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1346832/
https://ncbi.nlm.nih.gov/pubmed/16378967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.80.2.643-653.2006
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items